KRAS and neoplasm: An increase in the CD8/CD4 tumor-infiltrating T-lymphocyte (TIL) ratio was observed in the peptide–lipoplex-treated group (Fig. 4a) and T cells in the spleen were KRAS-G12D-specific and did not respond to WT KRAS peptide (Fig. 4b).